Draadje OT, bijzaken & geleuter in de marge!
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
Ik was benieuwd hoe een oude bekende het deed... vertrokken na amper 1,5 jaar dienstverband.
Appointment of Dr Clive Dix as Executive Chairman and departure of Piers Morgan as CEO - www.c4xdiscovery.com/news/press-relea...
Interessant. Morgan werd als niet erg krachtig beschouwd in zijn tijd bij QURE. Daar lijkt dit een bevestiging van. Kon geloof ik wel goed geld op halen, maar als operationele CFO duidelijk minder...
Adeno-associated Vector Toxicity—To Be or Not to Be? www.nature.com/mt/journal/v23/n11/pdf...
Gisteren gezien, "must see" docu van Jeb Berrier: www.npo.nl/2doc-bag-it/04-12-2015/VAR... plastic bags/coffee cups Bag It!
What Does this Mean for BPX-501 vs. Gene Therapy for Orphan Blood Disorders?
The Company’s most recent presentation at the Jefferies Global Healthcare Conference made the case that BPX-501 enabled allogeneic HSCT is likely a better option than gene therapy for any major orphan non-malignant blood disorder. The only factor that favors gene therapy is that gene therapy is autologous and thus carries no risk of GvHD. However, as we can see from the ASH abstracts and the other literature on Alpha/Beta T cell depleted haploidentical HSCTs, GvHD risk is quickly becoming a non-issue in Alpha/Beta T depleted haplo HSCT in the context of BPX-501. All other factors heavily favor BPX-501 enabled HSCT. Crucially, HSCT is the only recognized curative measure for these patients.
The Company did a nice comparison of BPX-501 enabled HSCT and gene therapies in its presentation at the Jefferies conference in the table below:
Notably, HSCTs are relatively commonplace and adding BPX-501 is a minimal workflow change. It can address all of the hematologic indications that are currently being pursued by bluebird, UniQure, Dimension as well as other blood diseases with no gene therapy solution in clinical development. Gene therapy companies need to engineer distinct therapies for most every condition, gain approval on a disease by disease basis and have a far higher fundamental risk of potentially not being curative. If BPX-501 enabled haplo HSCT is as safe as it appears, it will likely be approved first and be considered first line for all of these indications. Moreover, gene therapies, likely second line, would possibly be evaluated in the context of a BPX-501 enabled HSCT alternative for patients by regulators. This could materially complicate things for gene therapies in these indications.
Hematopoietic stem cell transplantation (HSCT) remains a dangerous procedure with many possible complications; it is reserved for patients with life-threatening diseases. As survival following the procedure has increased, its use has expanded beyond cancer, such as autoimmune diseases.
Dus maar even afwachten hoor...
En $QURE heeft altijd nog CNS/Cardio
Dank je wel Doc.Er stonden zoveel enthousiaste reacties tav Sullivan's blog.
Een ander gevalletje: oei, als QURE dat maar niet overkomt. Stond ook even ruim boven de 30 dollar, nu onder de 7 dollar.
Zafgen (ZFGN) Stock Tanks as Second Patient Dies in Drug Study
@prof: asjeblief, niet zo paniekerig, da's slecht voor mijn eetlust; zafgens compound heeft niets met gentherapie te maken; de veiligheid van de huidige generatie gentherapieën is genoegzaam aangetoond;
@flosz: sullivan is wsch een frontrunner; er kan vast geld mee verdiend worden als je een goede timing hebt; maar als je al in de verleiding bent zou ik zeer voorzichtig zijn; denk niet dat ze QURE en de anderen de loef gaan afsteken;
Andere genafwijkingen. RARE CONNECT.
PB zonder Aicha..., vermelding e.mulder@uniQure.com. Lijkt me Eva (Maria) Mulder: @evamulder91
Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not 5, 9 or rh10
flosz schreef op 26 januari 2016 13:40:
Big Pharma’s worst nightmarewww.theguardian.com/society/2016/jan/...
Prachtig, flosz, bedankt.
Voor de geïnteresseerden:
* Gene-editing technique successfully stops progression of Duchenne muscular dystrophy
Using a new gene-editing technique, a team of scientists from UT Southwestern Medical Center stopped progression of Duchenne muscular dystrophy (DMD) in young mice.
If efficiently and safely scaled up in DMD patients, this technique could lead to one of the first successful genome editing-based treatments for this fatal disease, researchers said.
DMD, the most common and severe form of muscular dystrophy among boys, is characterized by progressive muscle degeneration and weakness. It is caused by mutations in the X-linked DMD gene that encodes the protein dystrophin. The disease affects one in 3,500 to 5,000 boys, according to the Centers for Disease Control and Prevention and other estimates, and often leads to premature death by the early 30s.
Although the genetic cause of DMD has been known for nearly 30 years, no effective treatments exist. The disease breaks down muscle fibers and replaces them with fibrous or fatty tissue, causing the muscle to gradually weaken. This condition often results in heart muscle disease, or cardiomyopathy, the leading cause of death in these patients.
In the study published in Science, UTSW researchers used a gene-editing approach to permanently correct the DMD mutation that causes the disease in young mice.
“This is different from other therapeutic approaches, because it eliminates the cause of the disease,” said senior author Dr. Eric Olson, Chairman of Molecular Biology, and Co-Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center at UT Southwestern.
In 2014, Dr. Olson’s team first used this technique — called CRISPR/Cas9-mediated genome editing — to correct the mutation in the germ line of mice and prevent muscular dystrophy. This paved the way for novel genome editing-based therapeutics in DMD. It also raised several challenges for clinical applications of gene editing. Since germ line editing is not feasible in humans, strategies would need to be developed to deliver gene-editing components to postnatal tissues.
To test this out, researchers delivered gene-editing components to the mice via adeno-associated virus 9 (AAV9). DMD mice treated with this technique produced dystrophin protein and progressively showed improved structure and function of skeletal muscle and heart.
“AAV9 can efficiently infect humans in a tissue-specific manner, but it does not cause human disease or toxicity. It’s a molecular missile for gene therapy,” said Dr. Leonela Amoasii, a postdoctoral researcher in the Olson lab and co-lead author of the study with Dr. Chengzu Long, Instructor of Molecular Biology.
“The CRISPR/Cas9 system is an adaptive immune system of single-celled organisms against invading virus. Ironically, this system was hijacked, we packaged it into a nonpathogenic virus, and corrected a genetic mutation in an animal model,” added Dr. Long.
The CRISPR genome-editing technology, which was developed by a researcher at University of California at Berkeley, was picked as the “Breakthrough of the Year” scientific development by Science.
“This study represents a very important translational application of genome editing of DMD mutations in young mice. It’s a solid step toward a practical cure for DMD,” said Dr. Rhonda Bassel-Duby, Professor of Molecular Biology and Co-Principal Investigator of a genomic editing project with Dr. Olson at the Wellstone Center.
“Importantly, in principle, the same strategy can be applied to numerous types of mutations within the human DMD patients,” added Dr. Olson, who also serves as Director of the Hamon Center for Regenerative Science and Medicine, and holds the Annie and Willie Nelson Professorship in Stem Cell Research, the Pogue Distinguished Chair in Research on Cardiac Birth Defects, and the Robert A. Welch Distinguished Chair in Science.
Now, the research team is working to apply this gene-editing technique to cells from DMD patients and in larger preclinical animal models.
This marks the first major finding of the UTSW Wellstone Center, which was recently established with $7.8 million in funding from the National Institutes of Health. UTSW is one of six Wellstone Centers across the country, which work to translate scientific findings and technological developments into novel treatments for muscular dystrophy, and to promote basic, translational, and clinical research. UT Southwestern’s Wellstone Center focuses on Duchenne muscular dystrophy.
“The recent groundbreaking discoveries from the Olson laboratory using genome editing to correct the genetic mutation that causes DMD have accelerated the race to find a cure for this deadly disease,” said Dr. Pradeep Mammen, Associate Professor of Internal Medicine and Co-Director of the UTSW Wellstone Center. “The challenge now lies before Wellstone Center researchers to translate these discoveries in the mouse model of DMD into a therapy for patients with DMD.”
www.sciencedaily.com/ Science Daily
www.sciencedaily.com/releases/2016/01... Original web page at Science Daily
Frenky, domme vraag misschien, maar suggereer je dat QURE zich hier op kan werpen met hun vector know how?
2011-2015:What a Fantastic 5 Years for European Biotech:first gene therapy treatment, first Immuno-oncology treatment, CAR-T, CRISPR and more… tinyurl.com/hh9q9gn
Diego Ardigo, Chiesi Farmaceutici: $QURE GT Hem.B, Glybera
#CGT2016 $QURE Alec Orphanidis & Christian Meyer twitter.com/floszcrxl/status/69239219...
The 2016 Sector Forecast: Upcoming Clinical Data Events m.youtube.com/watch?list=PLbTBF__p6d_... Regenerative Med., Gene Therapy
$BMY 2015 Fourth Quarter Results Conference Call
January 28, 2016 Time: 10:30 AM EST
Direct naar Forum